Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy

4 p | 10 | 1

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial

10 p | 13 | 1

Long term progression-free survival in anaplastic lymphoma kinase positive non small cell lung cancer patient treated with Crizotinib

3 p | 1 | 0